Prostacyclin administration during cardiopulmonary bypass in man.
In a double-blind trial prostacyclin was given to 12 of 23 patients undergoing coronary vein grafting. The treatment group showed a preservation of platelet number and function, with a halving of blood loss in the first 18 h postoperatively. The heparin sparing effect of prostacyclin was confirmed, as were the vasodilator effects which were not troublesome.
D000328:Adult; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003331:Coronary Vessels / Q000601:surgery; D004311:Double-Blind Method; D011464:Epoprostenol / Q000627:therapeutic use*; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count; D011453:Prostaglandins / Q000627:therapeutic use*; D011897:Random Allocation; D013921:Thrombocytopenia / Q000517:prevention & control; D014664:Vasodilation / Q000187:drug effects
D011453:Prostaglandins; D011464:Epoprostenol